Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

Kidney transplantation is the preferred treatment for suitable patients with end-stage renal disease; however, access to transplantation declines dramatically with increasing HLA sensitization. While the acceptable mismatch (AM) program by Eurotransplant improves transplantability for highly sensiti...

Descrición completa

Detalles Bibliográficos

Principais autores:	Stefan Reuter, Louise Benning, Andrea Dick, Lisa-Marie Dilz, Gunilla Einecke, Florian Emmerich, Florian Grahammer, Rebecca Großmann, Wilfried Gwinner, Fabian Halleck, Michael Hallensleben, Falko M. Heinemann, Bernd Jänigen, Dennis Kannenkeril, Teresa Kauke, Reinhard Kelsch, Stephan Kemmner, Malte Andreas Kluger, Jan Kowald, Andreas Kribben, Claudia Lehmann, Monika Lindemann, Giancarlo Maccagno, Christian Morath, Anja Mühlfeld, Lien Pham, Lutz Renders, Stefan Schaub, Sabine Scherer, Christian Seidl, Bernd Spriewald, Dirk Stippel, Julian Stumpf, Thuong Hien Tran, Rolf Weimer, Benjamin Wilde, Daniel Zecher, Malte Ziemann, Svitlana Ziganshyna, Nils Lachmann, Klemens Budde
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-06-01
Series:	Frontiers in Immunology
Assuntos:	delisting highly sensitized patient HLA incompatibility imlifidase kidney transplantation
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1846251/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!